Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20030575 | 0.92 | METAP2 (0.33) | ESR1METAP2HPGDTSHRMAPK1 | |
| SCHEMBL21654585 | 0.90 | RAB9A (0.34) | ESR1HPGDTSHRNPC1RAB9A | |
| SCHEMBL21654536 | 0.86 | METAP2 (0.33) | ESR1METAP2HPGDTSHRMAPK1 | |
| SCHEMBL21654576 | 0.85 | RAB9A (0.43) | ESR1METAP2HPGDTSHRMAPK1 | |
| SCHEMBL20030388 | 0.85 | NPC1 (0.31) | ESR1HPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21654780 | 0.85 | PTK2 (0.43) | ESR1METAP2HPGDTSHRNPC1 | |
| SCHEMBL21654517 | 0.84 | ESR1 (0.34) | ESR1METAP2HPGDTSHRNPC1 | |
| SCHEMBL21654700 | 0.83 | RAB9A (0.42) | ESR1HPGDTSHRNPC1RAB9A | |
| SCHEMBL21654582 | 0.82 | HPGD (0.34) | ESR1HPGDTSHRMAPK1NPC1 | |
| SCHEMBL21654782 | 0.81 | KMT2A (0.43) | HPGDTSHRNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149033-B2 | Heteroaryl compound, enantiomer, diastereomer or pharmaceutically acceptable salt thereof, and antiviral composition containing same as active ingredient | INSTITUT PASTEUR KOREA (KR) | 2021-10-19 | — | — | US | disclosed |
| US-20200031816-A1 | NOVEL HETEROARYL COMPOUND, ENANTIOMER, DIASTEREOMER OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND ANTIVIRAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | ST PHARM CO., LTD. (KR) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031816-A1 | NOVEL HETEROARYL COMPOUND, ENANTIOMER, DIASTEREOMER OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND ANTIVIRAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | ZC3HAV1, ZC3HAV1L, HAVCR2 | ESR1 4858/4885METAP2 268/4885HPGD 4213/4885 |
| US-11149033-B2 | Heteroaryl compound, enantiomer, diastereomer or pharmaceutically acceptable salt thereof, and antiviral composition containing same as active ingredient | ZC3HAV1, ZC3HAV1L, HAVCR2 | ESR1 4851/4885METAP2 270/4885HPGD 3730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.